Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20μg and drospirenone 3mg

Clinical Drug Investigation

Volumn 26, Issue 3, 2006, Pages 143-150

  Cibula, D ^a   Karck, U ^b   Weidenhammer, H G ^c   Kunz, J ^d   Alincic, S ^e   Marr, J ^e  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Klarastr   (Germany)

^d Zollikerberg Hospital   (Switzerland)

^e BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; DROSPIRENONE; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; HUMANS; PATIENT COMPLIANCE; PATIENT SATISFACTION;

EID: 33745585200     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/00044011-200626030-00004     Document Type: Article

References (24)

1. Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Stewart F, editors. Contraceptive technology. 17th revised ed. New York (NY): Ardent Media Inc., 1998: 779-844
2. Shvarts S, Besinque K, Atkinson R, et al. New advances in contraception. J Continuing Education 2002; 11-22
3. Rosenberg MJ, Waugh MS, Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J Reprod Med 1995 May; 40 (5): 355-60
4. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998 Sep; 179 (3 Pt 1): 577-82
5. Thorneycroft IH. Yasmin: the reason why. Eur J Contracept Reprod Health Care 2002 Dec; 7 Suppl. 3: 13-8
6. Muhn P, Krattenmacher R, Beier S, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity: pharmacological characterization in animal models. Contraception 1995 Feb; 51 (2): 99-110
7. Fuhrmann U, Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996 Oct; 54 (4): 243-51
8. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000 Feb; 61 (2): 105-11
9. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000 Mar; 5 (1): 25-34
10. Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either dros pirenone or desogestrel. Eur J Contracept Reprod Health Care 2000 Jun; 5 (2): 124-34
11. van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002 Apr; 69 (4 Suppl.): 2-15
12. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004 Aug; 74 (2): 123-30
13. Gerlinger C, Endrikat J, van der Meulen EA, et al. Recommendation for confidence interval and sample size calculation for the Pearl Index. Eur J Contracept Reprod Health Care 2003 Jun; 8 (2): 87-92
14. Archer DF, Maheux R, DelConte A, et al. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micro-grams. North American Levonorgestrel Study Group (NALSG). Contraception 1997 Mar; 55 (3): 139-44
15. Archer DF, Maheux R, DelConte A, et al. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl es-tradiol (Alesse). North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol 1999 Nov; 181 (5 Pt 2): 39-44
16. Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol 1993 Sep; 100 (9): 832-8
17. Endrikat J, Dusterberg B, Ruebig A, et al. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 1999 Nov; 60 (5): 269-74
18. The Mircette Study Group. An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low dose estrogen-progestin oral contraceptive. Am J Obstet Gynecol 1998 Jul; 179 (1): S2-8
19. Endrikat J, Jaques MA, Mayerhofer M, et al. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micro-grams gestodene and 20 micrograms ethinylestradiol/150 mi-crograms desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995 Oct; 52 (4): 229-35
20. Dusterberg B, Ellman H, Muller U, et al. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing ges-todene. Gynecol Endocrinol 1996 Feb; 10 (1): 33-9
21. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003 Aug; 68 (2): 89-96
22. Bounds W, Vessey M, Wiggins P. A randomized double-blind trial of two low dose combined oral contraceptives. Br J Obstet Gynaecol 1979 Apr; 86 (4): 325-9
23. Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 1997 Mar; 55 (3): 131-7
24. Endrikat J, Cronin M, Gerlinger C, et al. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel. Contraception 2001 Sep; 64 (3): 201-7